ATE140966T1 - Neuer neurotropischer faktor - Google Patents

Neuer neurotropischer faktor

Info

Publication number
ATE140966T1
ATE140966T1 AT91918727T AT91918727T ATE140966T1 AT E140966 T1 ATE140966 T1 AT E140966T1 AT 91918727 T AT91918727 T AT 91918727T AT 91918727 T AT91918727 T AT 91918727T AT E140966 T1 ATE140966 T1 AT E140966T1
Authority
AT
Austria
Prior art keywords
designated
useful
new
neurotropic factor
diagnostics
Prior art date
Application number
AT91918727T
Other languages
English (en)
Inventor
Arnon Rosenthal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/587,707 external-priority patent/US5364769A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE140966T1 publication Critical patent/ATE140966T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT91918727T 1990-09-25 1991-09-24 Neuer neurotropischer faktor ATE140966T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/587,707 US5364769A (en) 1990-09-25 1990-09-25 Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US64848291A 1991-01-31 1991-01-31

Publications (1)

Publication Number Publication Date
ATE140966T1 true ATE140966T1 (de) 1996-08-15

Family

ID=27080108

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91918727T ATE140966T1 (de) 1990-09-25 1991-09-24 Neuer neurotropischer faktor

Country Status (11)

Country Link
US (2) US5830858A (de)
EP (1) EP0550665B1 (de)
JP (5) JPH06501617A (de)
AT (1) ATE140966T1 (de)
AU (1) AU654302B2 (de)
CA (1) CA2092567C (de)
DE (1) DE69121208T2 (de)
DK (1) DK0550665T3 (de)
ES (1) ES2093112T3 (de)
GR (1) GR3021371T3 (de)
WO (1) WO1992005254A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
CA2092567C (en) * 1990-09-25 2007-07-03 Arnon Rosenthal Nt-4 neurotrophic factor
WO1992020797A1 (en) * 1991-05-20 1992-11-26 Case Western Reserve University Neurotrophic factor, preparation and uses thereof
JPH08510987A (ja) * 1991-05-21 1996-11-19 リジェネロン ファーマシューティカルズ，インコーポレーテッド ニューロトロフィン−４発現に基く治療および診断方法
PT100580A (pt) * 1991-06-12 1993-09-30 Regeneron Pharma Producao e recuperacao de neurotrofinas recombinantes
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
EP0644937A4 (en) * 1992-06-12 1995-05-03 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression.
DK0662146T3 (da) * 1992-09-03 2000-11-13 Univ California Dorsalvævpåvirkende faktor og præparat
ATE190352T1 (de) * 1992-09-03 2000-03-15 Regeneron Pharma Dorsalgewebe beeinflussender faktor und zusammensetzungen
US5470719A (en) * 1994-03-18 1995-11-28 Meng; Shi-Yuan Modified OmpA signal sequence for enhanced secretion of polypeptides
AU3564595A (en) * 1994-09-12 1996-03-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Biologically active molecules derived from neurotrophins
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AU729459B2 (en) * 1996-11-15 2001-02-01 Genentech Inc. Purification of neurotrophins
US6391312B1 (en) 1997-01-23 2002-05-21 Sumitomo Pharmaceuticals Co., Limited Remedies for diabetes
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7037493B2 (en) 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US6852323B2 (en) * 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
GB0024550D0 (de) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7112668B2 (en) 2001-01-23 2006-09-26 Curagen Corporation Polypeptides and nucleic acids encoded thereby
WO2002081517A2 (en) * 2001-01-19 2002-10-17 Curagen Corporation Novel polypeptides and nucleic acids encoded thereby
US7211395B2 (en) * 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
EP1262188A1 (de) * 2001-05-22 2002-12-04 Centre National De La Recherche Scientifique (Cnrs) Verbesserter neuronaler Gentransfer
US7576065B2 (en) * 2002-02-15 2009-08-18 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
US20040071705A1 (en) * 2002-06-21 2004-04-15 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
AU2007210862A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
CA2672750A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
EP3774858B1 (de) 2018-03-29 2025-07-30 MyNeuroCure Oy C-terminale cdnf-fragmente mit neuroprotektiver wirkung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3113963A1 (de) * 1981-04-07 1982-10-21 Günter Horst 7927 Sontheim Röhm "vorrichtung zum absaugen von bohrmehl an der bohrstelle eines bohrers"
US4699875A (en) * 1982-11-24 1987-10-13 Baylor College Of Medicine Diagnosis of amyotrophic lateral sclerosis by neurotrophic factors
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
CA2092567C (en) * 1990-09-25 2007-07-03 Arnon Rosenthal Nt-4 neurotrophic factor
WO1992020797A1 (en) * 1991-05-20 1992-11-26 Case Western Reserve University Neurotrophic factor, preparation and uses thereof
JPH08510987A (ja) * 1991-05-21 1996-11-19 リジェネロン ファーマシューティカルズ，インコーポレーテッド ニューロトロフィン−４発現に基く治療および診断方法
PT100580A (pt) * 1991-06-12 1993-09-30 Regeneron Pharma Producao e recuperacao de neurotrofinas recombinantes
EP0644937A4 (en) * 1992-06-12 1995-05-03 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression.

Also Published As

Publication number Publication date
ES2093112T3 (es) 1996-12-16
WO1992005254A1 (en) 1992-04-02
CA2092567C (en) 2007-07-03
US6037320A (en) 2000-03-14
EP0550665A1 (de) 1993-07-14
JP2004344175A (ja) 2004-12-09
GR3021371T3 (en) 1997-01-31
AU654302B2 (en) 1994-11-03
DK0550665T3 (da) 1996-12-02
US5830858A (en) 1998-11-03
JP2006087434A (ja) 2006-04-06
AU8756491A (en) 1992-04-15
DE69121208D1 (de) 1996-09-05
EP0550665B1 (de) 1996-07-31
JPH06501617A (ja) 1994-02-24
JP2003159083A (ja) 2003-06-03
DE69121208T2 (de) 1997-01-23
JP2007209349A (ja) 2007-08-23
CA2092567A1 (en) 1992-03-26

Similar Documents

Publication Publication Date Title
DE69121208D1 (de) Neuer neurotropischer faktor
DE3586189D1 (de) Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
EP0962531A3 (de) Isoliertes Polypeptidfragment, das die Interferon-gamma Produktion induziert, und für das Polypeptid kodierende DNA
DE3587422D1 (de) Fuer ein hirudinaehnliches protein kodierende dns-sequenz und verfahren zur herstellung eines solchen proteins.
DE343684T1 (de) Interleukin-1-inhibitoren.
LTIP828A (en) Nucleic acid fragment which codes for human proapolipoprotein a-1
DE68925083D1 (de) Rekombinante DNS, diese rekombinante DNS enthaltender Mikroorganismus und Verfahren zur Herstellung von L-Aminosäure unter Verwendung dieses Mikroorganismus
OA07233A (fr) Interféron immunitaire humain.
CA2108473A1 (en) Heregulins (hrgs) binding proteins of p185erb2
DE3854952D1 (de) Mykobakterielle rekombinanten und peptide
CA2175332A1 (en) Haemophilus transferrin receptor genes
DK0506574T3 (da) Protein med aktivitet af cytokintype, rekombinant-DNA, der koder for dette protein, celler og transformerede mikroorganismer
ATE481489T1 (de) Für den export verzweigtkettiger aminosäuren kodierende nukleotidsequenzen, verfahren zu deren isolierung und ihre verwendung
DE3786649D1 (de) Pferde-gamma-interferon.
ES8703520A1 (es) Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas
FI90667C (fi) Menetelmä valmistaa uutta ihmisen tyypin I interferoniproteiinia
NO177570C (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
PT85565A (en) Amylolytic enzymes producing microorganisms constructed by recombinant dna technology and their use for fermentation processes
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
DE3576523D1 (de) Rekombinante dna enthaltende coryneformbakterien und verfahren zur herstellung von aromatischen aminosaeuren unter verwendung dieser bakterien.
ATE122055T1 (de) Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung.
ES2115208T3 (es) Proteina de la superficie celular de brevibacterium lactofermentum.
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
ATE61819T1 (de) Rekombinante dns, enthaltend ein herpes-simplex- virus-gen oder ein fragment davon, hefe transformiert mit dieser rekombinanten dns und verfahren zur herstellung von herpes-simplex- virus-proteinen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time